Thomas Nösslinger

3.9k total citations · 1 hit paper
49 papers, 1.6k citations indexed

About

Thomas Nösslinger is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Thomas Nösslinger has authored 49 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 25 papers in Genetics and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Thomas Nösslinger's work include Acute Myeloid Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (16 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Thomas Nösslinger is often cited by papers focused on Acute Myeloid Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (16 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Thomas Nösslinger collaborates with scholars based in Austria, Germany and Croatia. Thomas Nösslinger's co-authors include Michael Pfeilstöcker, Peter Valent, Reinhard Stauder, Friedrich Wimazal, Aristoteles Giagounidis, Michael Lübbert, Otto Krieger, Christian Steidl, Christa Fonatsch and Carlo Aul and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Thomas Nösslinger

43 papers receiving 1.6k citations

Hit Papers

New insights into the prognostic impact of the karyotype ... 2007 2026 2013 2019 2007 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
    2007 540 citations Michael Pfeilstöcker, Thomas Nösslinger et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Nösslinger Austria 17 1.4k 684 498 255 223 49 1.6k
Otto Krieger Austria 14 1.2k 0.8× 528 0.8× 328 0.7× 271 1.1× 197 0.9× 37 1.5k
Andrea Kündgen Germany 19 2.1k 1.5× 1.1k 1.5× 655 1.3× 231 0.9× 175 0.8× 50 2.4k
Eva Löfvenberg Sweden 18 988 0.7× 813 1.2× 362 0.7× 244 1.0× 229 1.0× 32 1.4k
Fernando Ramos Spain 21 1.2k 0.8× 347 0.5× 524 1.1× 201 0.8× 141 0.6× 68 1.5k
Leonie Saft Sweden 16 875 0.6× 405 0.6× 298 0.6× 118 0.5× 148 0.7× 37 1.1k
G. John Swansbury United Kingdom 25 1.3k 0.9× 655 1.0× 583 1.2× 270 1.1× 411 1.8× 43 2.0k
Pascale Lepelley France 21 742 0.5× 299 0.4× 376 0.8× 366 1.4× 105 0.5× 51 1.2k
Sefer Gezer United States 15 1.1k 0.7× 327 0.5× 543 1.1× 138 0.5× 43 0.2× 29 1.3k
FR Davey United States 14 1.1k 0.8× 391 0.6× 372 0.7× 266 1.0× 227 1.0× 32 1.6k
Margherita Maffioli Italy 20 2.5k 1.7× 2.5k 3.7× 1.4k 2.8× 170 0.7× 126 0.6× 61 3.1k

Countries citing papers authored by Thomas Nösslinger

Since Specialization
Citations

This map shows the geographic impact of Thomas Nösslinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Nösslinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Nösslinger more than expected).

Fields of papers citing papers by Thomas Nösslinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Nösslinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Nösslinger. The network helps show where Thomas Nösslinger may publish in the future.

Co-authorship network of co-authors of Thomas Nösslinger

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Nösslinger. A scholar is included among the top collaborators of Thomas Nösslinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Nösslinger. Thomas Nösslinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Keil, Felix, Antonia Müller, Andrea Berghold, et al.. (2023). BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial. EClinicalMedicine. 66. 102318–102318.
3.
Heibl, Sonja, Bettina Gisslinger, Peter Bettelheim, et al.. (2020). Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. Cancers. 12(7). 1891–1891. 4 indexed citations
4.
Gebhart, Johanna, Klaus Lechner, Cathrin Skrabs, et al.. (2014). Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma. Thrombosis Research. 134(5). 980–984. 13 indexed citations
5.
Burgstaller, Sonja, Peter Bettelheim, Otto Krieger, et al.. (2014). 10th anniversary of the Austrian MDS Platform: aims and ongoing projects. Wiener klinische Wochenschrift. 127(1-2). 12–15. 1 indexed citations
6.
Hopfinger, Georg, Thomas Nösslinger, Alois Lang, et al.. (2014). Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Annals of Hematology. 93(3). 459–462. 44 indexed citations
7.
Sperr, Wolfgang R., Georg Kemmler, Friedrich Wimazal, et al.. (2014). Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. Journal of Geriatric Oncology. 5(3). 299–306. 16 indexed citations
8.
Pfeilstöcker, Michael, et al.. (2011). Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes. Leukemia Research. 36(2). 132–139. 14 indexed citations
9.
Nösslinger, Thomas, Heinz Tüchler, Ulrich Germing, et al.. (2009). Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Annals of Oncology. 21(1). 120–125. 46 indexed citations
10.
Wimazal, Friedrich, Thomas Nösslinger, Christian Baumgärtner, et al.. (2009). Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. European Journal of Clinical Investigation. 39(5). 406–411. 21 indexed citations
11.
Sperr, Wolfgang R., Friedrich Wimazal, Michael Kundi, et al.. (2009). Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Annals of Oncology. 21(1). 114–119. 80 indexed citations
12.
Stauder, Reinhard, Friedrich Wimazal, Thomas Nösslinger, et al.. (2008). Die individualisierte Riskoeinschätzung und Therapieplanung bei myelodysplastischen Syndromen. Wiener klinische Wochenschrift. 120(17-18). 523–537. 8 indexed citations
13.
Valent, Peter, O. Krieger, Reinhard Stauder, et al.. (2008). Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. European Journal of Clinical Investigation. 38(3). 143–149. 44 indexed citations
14.
Kaufmann, H., J Ackermann, Verena Sagaster, et al.. (2007). Cytogenetic patterns in multiple myeloma after a phase of preceding MGUS. European Journal of Clinical Investigation. 38(1). 53–60. 3 indexed citations
15.
16.
Seidl, Sonja, Jutta Ackermann, H. Kaufmann, et al.. (2004). DNA‐methylation analysis identifies the E‐cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer. 100(12). 2598–2606. 56 indexed citations
17.
18.
Kaufmann, H., Elisabeth Krömer, Thomas Nösslinger, et al.. (2003). Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma. European Journal Of Haematology. 71(3). 179–183. 24 indexed citations
19.
Pfeilstöcker, Michael, Heidrun Karlic, Thomas Nösslinger, et al.. (2002). Assessment of growth and differentiation processes in myelodysplastic syndromes by PCR analysis of Gα16 and 5′-lipoxygenase. Annals of Hematology. 81(11). 632–640. 2 indexed citations
20.
Pfeilstöcker, Michael, Thomas Nösslinger, Hadwiga Nowotny, et al.. (1999). Cross‐validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. British Journal of Haematology. 106(2). 455–463. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Otto Krieger Breakdown of academic impact, for papers by Andrea Kündgen Breakdown of academic impact, for papers by Eva Löfvenberg Breakdown of academic impact, for papers by Fernando Ramos Breakdown of academic impact, for papers by Leonie Saft Breakdown of academic impact, for papers by G. John Swansbury Breakdown of academic impact, for papers by Pascale Lepelley Breakdown of academic impact, for papers by Sefer Gezer Breakdown of academic impact, for papers by FR Davey Breakdown of academic impact, for papers by Margherita Maffioli
Rankless by CCL
2026